How should I manage a patient with a first-time elevated low-density lipoprotein cholesterol of 137 mg/dL and an elevated hematocrit?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Management of First-Time Elevated LDL-C 137 mg/dL with Elevated Hematocrit

Start with therapeutic lifestyle changes immediately and assess the patient's 10-year ASCVD risk to determine if statin therapy is indicated, while simultaneously investigating the elevated hematocrit as a potential secondary cause of dyslipidemia. 1

Immediate Steps for LDL-C Management

1. Risk Stratification

Calculate the patient's 10-year ASCVD risk using validated tools (age 40-75 years) before initiating pharmacotherapy 1, 2. The decision pathway depends on:

  • Age and baseline risk factors (smoking, hypertension, diabetes, family history)
  • Presence of risk-enhancing factors that may guide treatment intensity
  • Absolute LDL-C level (137 mg/dL is borderline-high but not severe)

2. Rule Out Secondary Causes

The elevated hematocrit is particularly important here—you must obtain 3:

  • Thyroid function tests (TSH) - hypothyroidism causes both elevated LDL-C and can affect hematocrit
  • Liver function tests - hepatic disease affects lipid metabolism
  • Fasting glucose/HbA1c - diabetes is a major risk modifier
  • Renal function (creatinine, urinalysis) - chronic kidney disease affects both parameters
  • Medication review - certain drugs elevate lipids

The elevated hematocrit could indicate:

  • Polycythemia (primary or secondary)
  • Dehydration (which can falsely elevate LDL-C)
  • Chronic hypoxia/smoking
  • Testosterone use or other medications

Critical pitfall: Do not start statin therapy until secondary causes are excluded, as treating the underlying condition may normalize lipids.

Treatment Algorithm Based on Risk

For Low-Risk Patients (10-year ASCVD risk <5%)

  • LDL-C goal: <130 mg/dL 3
  • Initiate intensive therapeutic lifestyle changes:
    • Reduce saturated fat to <7% of total calories
    • Dietary cholesterol <200 mg/day
    • Add plant stanols/sterols (2 g/day) and viscous fiber (10-25 g/day)
    • Weight reduction if BMI ≥25 kg/m²
    • Physical activity: minimum 150 minutes/week moderate intensity 1
  • Reassess lipids in 12 weeks
  • Statin therapy only if LDL-C remains ≥190 mg/dL after lifestyle changes 3

For Moderate-Risk Patients (10-year ASCVD risk 5-10%)

  • LDL-C goal: <130 mg/dL 3, 4
  • Start with therapeutic lifestyle changes (as above)
  • Consider moderate-intensity statin if LDL-C remains ≥130 mg/dL after 12 weeks of lifestyle therapy 3
  • Optional goal of <100 mg/dL is reasonable based on newer evidence 4

For Moderately High-Risk Patients (10-year ASCVD risk 10-20%)

  • LDL-C goal: <130 mg/dL, with optional goal <100 mg/dL 4
  • Initiate therapeutic lifestyle changes
  • Start moderate-intensity statin if LDL-C ≥130 mg/dL 4
  • Consider statin therapy even for LDL-C 100-129 mg/dL as a therapeutic option 4

For High-Risk Patients (10-year ASCVD risk ≥20%, or diabetes, or established ASCVD)

  • LDL-C goal: <100 mg/dL 3, 2, 5
  • Start moderate-to-high intensity statin immediately without waiting for lifestyle changes 2, 6
  • For diabetes patients 40-75 years: start moderate-intensity statin if LDL-C ≥70 mg/dL 2, 6

Specific Recommendations for LDL-C 137 mg/dL

At 137 mg/dL, this patient falls into a gray zone where the decision hinges entirely on their calculated 10-year ASCVD risk and presence of risk enhancers 1, 2:

If 0-1 risk factors present:

  • Lifestyle modification alone
  • Recheck in 12 weeks
  • Statin only if persistently ≥160 mg/dL (or ≥190 mg/dL for drug therapy) 3

If ≥2 risk factors and 10-year risk 10-20%:

  • Lifestyle changes PLUS consider moderate-intensity statin now 4
  • Target <130 mg/dL (or optionally <100 mg/dL)

If diabetes or 10-year risk >20%:

  • Start statin immediately 2, 6
  • Target <100 mg/dL

Addressing the Elevated Hematocrit

Do not ignore this finding—it requires parallel investigation:

  1. Repeat hematocrit fasting and well-hydrated to confirm elevation
  2. Complete blood count with differential to characterize the polycythemia
  3. Assess for hypoxia: pulse oximetry, consider sleep apnea screening
  4. Smoking history: smoking causes both elevated hematocrit and dramatically increases ASCVD risk
  5. Consider referral to hematology if primary polycythemia suspected

The elevated hematocrit may actually increase this patient's cardiovascular risk beyond what the lipid profile suggests, as polycythemia increases blood viscosity and thrombotic risk.

Clinician-Patient Risk Discussion

Before starting any statin therapy, have a structured risk discussion 1, 2, 6:

  • Review major risk factors present
  • Discuss calculated 10-year and lifetime ASCVD risk
  • Explain that LDL-C reduction proportionally reduces events
  • Address statin safety concerns and side effects
  • Consider coronary artery calcium scoring if risk is uncertain (especially for intermediate-risk patients)

Common Pitfalls to Avoid

  1. Starting statins without risk assessment in patients with LDL-C 130-189 mg/dL
  2. Failing to screen for secondary causes before attributing dyslipidemia to primary disorder
  3. Ignoring the elevated hematocrit—this could be the key to both diagnoses
  4. Not emphasizing lifestyle changes—these remain foundational regardless of medication decisions 1, 2
  5. Treating the number instead of the patient—137 mg/dL may be acceptable in low-risk individuals but inadequate in high-risk patients

Follow-Up Timeline

  • Recheck fasting lipid panel in 12 weeks after lifestyle changes (if not starting statin) 3
  • Recheck in 4-12 weeks after starting statin to assess response and tolerability 2
  • Monitor hematocrit alongside lipid management
  • Reassess cardiovascular risk annually as risk factors evolve

The key message: LDL-C of 137 mg/dL is not automatically abnormal—context determines treatment. The elevated hematocrit demands investigation as it may reveal the underlying cause of dyslipidemia and independently affects cardiovascular risk.

References

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.